The FDA has granted Breakthrough Therapy designation to JNJ-6372 for the treatment of patients with NSCLC with EGFR Exon 20 insertion mutations.
The Food and Drug Administration has granted Priority Review for the supplemental New Drug Application (sNDA) for brigatinib (Takeda) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC).
The FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for atezolizumab (Tecentriq®; Genentech) as a first-line monotherapy in patients with advanced non-squamous and squamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations with high PD-L1 expression (TC3/IC3 wild-type [WT]), as determined by PD-L1 biomarker testing.
The FDA has accepted for Priority Review the NDA for lurbinectedin for the treatment of patients with small cell lung cancer who have progressed after prior platinum-containing therapy.
Volume-based, low-dose computed tomographic screening at various intervals may reduce the risk of lung cancer mortality in people who were current smokers or had a history of smoking.